Vercel Brings New Agent Framework, Full-Stack Capabilities, and Enterprise Controls to Its Agentic Infrastructure Platform
17.6.2026 12:13:00 CEST | Business Wire | Press Release
Today at Ship, its annual conference, Vercel introduced a set of new products that deepen its agentic infrastructure platform trusted by DoorDash, Helly Hansen, OpenAI, Stripe, and The Weather Company. Founder and CEO Guillermo Rauch and other Vercel leaders unveiled the lineup on stage, anchored by three shifts the products address: agents are now the dominant way software gets deployed, every application is becoming agentic, and enterprises need to run agents in production securely and at scale.
The transition is well underway. Six months ago, fewer than three percent of deployments to Vercel infrastructure were triggered by coding agents. Agents now account for more than half. Token volume through Vercel's AI Gateway has grown from roughly two trillion to twenty trillion per month over the same period. And over the past year, Vercel has invested heavily in Python and backend frameworks, with a growing share of customers now running backends and databases alongside their frontends.
"Each new generation of software needs a new generation of infrastructure. For the agent era, that's Vercel," said Rauch. "Vercel is where coding agents deploy software, where teams build and deploy their own full-stack apps and agents, and, increasingly, a place where Vercel itself can autonomously monitor your software once you deploy."
What's launching at Ship:
- Vercel Services lets teams deploy backends, frontends, and other services as part of a single project, with the ability to communicate with each other privately without ever touching the public internet. Secure authentication is handled automatically. One commit yields a single preview URL for the entire application. Customers like OpenAI and Octopus Energy run Next.js frontends with Python backends entirely on Vercel. Available in Beta on July 1st.
- The Agent Stack is the name for Vercel's widely used AI tooling (AI SDK, AI Gateway, Vercel Sandbox, Workflow SDK, and Chat SDK) now complemented byVercel Connect, which replaces long-lived credentials with scoped, short-lived tokens and full audit trails. Connect launches with integrations for Slack, GitHub, Snowflake, Salesforce, Notion, and Linear, with any other service addable via OAuth or API.
- eve is an opinionated, open-source agent framework, described on stage as "Next.js for agents." An agent becomes simply a directory, with durability, sandboxed compute, agent tools, skills, integrations, and human-in-the-loop approvals built in. Work that took days to scaffold now takes minutes.
- Vercel Agent uses AI to proactively help developers manage their application and agent infrastructure. Because Vercel runs apps in production, it can use traffic, traces, and alerts to investigate issues autonomously and surface pull requests, not just alerts. Vercel Agent can correlate an incident to the deployment that caused it and recommend a fix for human approval. It runs with its own scoped identity and is read-only by default. Available in Beta today.
- Vercel for Enterprise Apps and Agents packages the full stack for enterprise use, with IDP-backed identity and access controls and the option to deploy within a company's own AWS account. It includes Enterprise Managed Users, which provides global management of Vercel and v0 users, and Vercel Passport, which keeps internal apps and agents behind a company's identity provider by default.
Today's launches are how Vercel delivers on its agentic infrastructure vision. The company has spent the last decade removing operational friction between an idea and a running system: first for websites, then for full-stack applications, and now for agents. With Vercel Services, the Agent Stack, eve, Vercel Agent, and Vercel for Enterprise Apps and Agents, that platform becomes a single place to build, ship, and run agentic software at scale. To learn more, visit vercel.com.
About Vercel
Vercel is agentic infrastructure for every app and agent. As the team behind Next.js, AI SDK, and v0, Vercel is where humans and agents build and deploy software together. We free Adobe, Notion, and millions of developers worldwide to ship what's next.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260617093685/en/
Contacts
press@vercel.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press Release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press Release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press Release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press Release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press Release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom